Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|AOST1321||COG||Phase II Study of Denosumab (IND #127430; NSC# 744010); a RANK Ligand Antibody; for Recurrent or Refractory Osteosarcoma||Pediatric CIRB||Available to Open|
|URCC-16092||NCORP-University of Rochester Cancer Center||Phase II Study of Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy||Cancer Prevention and Control CIRB||Available to Open|
|A041703||Alliance||Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA5162||ECOG-ACRIN||Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR||Adult CIRB - Early Phase Emphasis||Available to Open|
|10240||ETCTN||Phase II Study of XL184 (cabozantinib) in combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after One Prior VEGFR-Targeted Therapy||Adult CIRB - Early Phase Emphasis||Available to Open|
|S1605||SWOG||Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A071601||Alliance||Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|9653||ETCTN||Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Unrothelial Carcinoma of the Bladder||Adult CIRB - Early Phase Emphasis||Completed|
|AEWS0621||COG||Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults with Recurrent or Refractory Ewing Sarcoma||Pediatric CIRB||Completed|
|A031803||Alliance||Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|